Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Receives “Outperform” Rating from William Blair

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)‘s stock had its “outperform” rating restated by William Blair in a report released on Wednesday,RTT News reports.

Separately, UBS Group boosted their price objective on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Trading Up 1.8 %

Shares of TLX stock traded up $0.30 during mid-day trading on Wednesday, hitting $17.05. The company’s stock had a trading volume of 13,383 shares, compared to its average volume of 27,834. The stock’s fifty day simple moving average is $17.35. Telix Pharmaceuticals Limited American Depositary Shares has a 52 week low of $14.01 and a 52 week high of $30.36.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.